SK bioscience : Conclusion of Single SalesContract or Supply Contract

Conclusion of Single Sales Contract or Supply Contract

1. Type of sales or supply contract	Other sales or supply contracts
- Name of contract concluded	Government advance purchase agreement for COVID-19 vaccine (GBP510)
2. Details of contract	Contract amount (KRW)	200,000,000,000
Sales of the latest fiscal year (KRW)	225,610,784,857
Ratio to sales (%)	88.65
Classified as a large-sized corporation?	No
3. Counterparty to contract	Korea Disease Control and Prevention Agency
- Relationship to company	-
4. Regions of sales or supply (markets served)	Republic of Korea
5. Contract period	Start date	2022-03-21
End date	-
6. Terms and conditions of contract	Supply of a COVID-19 vaccine (GBP510) developed and produced by SK Bioscience
7. Effective date of contract (receipt of orders)	2022-03-21
8. Withholding of disclosure	Reasons for withholding disclosure	-
Withholding period	-
9. Other matters to be factored into investment decisions
- The sales of the latest fiscal year above are based on individual financial statements as of the end of 2020. - The contract amount above may change by mutual agreement between the contracting parties, and the amount may change when the contract quantity is changed. - The contract above may be terminated if Korean licensing and authorization are not obtained by the end of December 2022 or within the period extended by a separate agreement between the contracting parties. - The end date of the contract period above is 24 months from the date of licensing and authorization, and can be extended by agreement between the contracting parties.
※ Related disclosure	-